1-2 of 2
Mike Royal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

SOR-CART-MM-001 Study: A Phase I, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Edward A. Stadtmauer, Omar Elghawy, Todd F. Roberts, Deepu Madduri, Sikander Ailawadhi, Mike Royal, Ying Yan
Journal: Blood
Blood (2023) 142 (Supplement 1): 6851.
https://doi.org/10.1182/blood-2023-178636
Published: 2023
Journal Articles

A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Multiple Myeloma

Rajshekhar Chakraborty, Ying Yan, Mike Royal
Journal: Blood
Blood (2021) 138 (Supplement 1): 4763.
https://doi.org/10.1182/blood-2021-150783
Published: 2021